Senti Biosciences (NASDAQ:SNTI) Announces Quarterly Earnings Results

Senti Biosciences (NASDAQ:SNTI) issued its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.22, FiscalAI reports. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million.

Senti Biosciences Price Performance

Shares of NASDAQ:SNTI opened at $1.01 on Friday. Senti Biosciences has a 1-year low of $0.77 and a 1-year high of $3.88. The company has a market capitalization of $31.46 million, a P/E ratio of -0.53 and a beta of 2.09. The firm’s 50 day simple moving average is $0.95 and its two-hundred day simple moving average is $1.22.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SNTI. Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Tuesday, April 21st. Finally, Chardan Capital boosted their target price on shares of Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Senti Biosciences has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Hedge Funds Weigh In On Senti Biosciences

Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in Senti Biosciences during the fourth quarter valued at approximately $46,000. Jane Street Group LLC purchased a new position in Senti Biosciences during the fourth quarter valued at approximately $40,000. Citadel Advisors LLC purchased a new position in Senti Biosciences during the third quarter valued at approximately $117,000. Armistice Capital LLC purchased a new position in Senti Biosciences during the second quarter valued at approximately $1,883,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares in the last quarter. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.